Geron CORP

Geron Corporation's stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing share availability, and re-elected three Class III directors at the 2026 Annual Meeting.

Geron Corporation announced the immediate election of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, enhancing governance and strategic oversight.

Geron Corporation announced fourth quarter and full year 2025 financial results, highlighting significant RYTELO revenue growth and a reduced net loss, alongside 2026 guidance.

Geron Corporation announced its 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million, alongside a reduction in operating expenses.

Geron Corporation amended its senior secured term loan facility, extending the availability of Tranches B and C and the makewhole date for prepayments.

Geron Corporation initiated a strategic restructuring plan, including a one-third workforce reduction, to improve financial discipline and create long-term shareholder value.

Geron Corporation announced its first quarter 2026 financial results, showing an increase in net product revenue for RYTELO, alongside continued investment in research and development.

Geron Corporation reported a significant increase in RYTELO product revenue for Q3 2025 and announced full enrollment in its pivotal Phase 3 IMpactMF clinical trial.

Geron Corporation reported a net loss of $16.4 million in Q2 2025, with RYTELO product revenue reaching $49.0 million, as the company continues its commercialization efforts and advances clinical trials.

Geron Corporation's Q1 2025 results reveal flat RYTELO sales growth and ongoing legal challenges, despite FDA and EC approvals.

Geron Corporation announces its Q3 2024 financial results, marked by the initial commercial launch of RYTELO and strategic financing agreements to support ongoing operations and development.

Geron Corporation announces its Q2 2024 financial results, marked by the FDA approval and initial commercial launch of RYTELO for lower-risk MDS, alongside updates on its clinical development programs.

Geron Corporation reported a significant reduction in net losses for 2025, driven by initial RYTELO sales, while navigating ongoing legal proceedings and a strategic workforce reduction.

Geron's 10-K filing highlights the commercial launch of RYTELO, its strategy to maximize its value, and ongoing clinical trials for other indications.

Geron Corporation's 10-K filing details its capital stock, potential anti-takeover measures, and the regulatory pathway for its lead drug candidate, imetelstat.

Robert J. Spiegel, a Director at Geron Corp, received 6,103 shares of common stock as compensation for his board services.

Robert J. Spiegel, a Director at Geron Corp, has acquired 220,000 stock options with an exercise price of $1.26, vesting on May 20, 2026.

Geron Corporation reports that Director Elizabeth G. O'Farrell was granted a stock option for 220,000 shares.

Geron Corporation director Susan Molineaux has acquired 220,000 stock options, with vesting contingent on continuous service and company meeting dates.

John F. McDonald, a Director at Geron Corp, has acquired 220,000 stock options with an exercise price of $1.26, exercisable on May 20, 2026.

Geron Corporation Director Dawn Carter has been granted a stock option for 220,000 shares of common stock.

Geron Corporation has announced its 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026, to elect directors, approve equity plan amendments, and ratify auditor selection.

Geron Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Geron Corporation is asking stockholders to vote on proposals including director elections and amendments to equity incentive plans at its upcoming virtual annual meeting on May 21, 2025.

Geron Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Geron Corporation will hold its annual stockholders meeting virtually on May 9, 2024, to vote on director elections, executive compensation, and auditor ratification.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 4.95% of Geron Corp's common stock as of March 31, 2026.

Soleus Capital has filed a Schedule 13G reporting a 6.5% beneficial ownership stake in Geron Corporation.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Geron Corp common stock following an internal realignment.

Soleus Capital Master Fund and its affiliates have reported a 5.2% beneficial ownership stake in Geron Corporation, totaling 33,008,659 shares.

Deep Track Capital, LP and affiliated entities have disclosed a 5.09% beneficial ownership stake in Geron Corp, totaling 32,511,271 shares.

Deep Track Capital and affiliates disclosed a 6.75% beneficial ownership stake in Geron Corp, holding 43 million shares as of June 30, 2025.